Expertise in
84
conditions

Enrico S. Bertini

Rome, IT 
Expertise in
84
conditions
Rome, IT 

Overview

Enrico Bertini practices practicing medicine in Rome, Italy.

Mr. Bertini is highly rated in 84 conditions, according to our data. His clinical expertise encompasses Spinal Muscular Atrophy (SMA), Drug Induced Dyskinesia, Becker Muscular Dystrophy, Gastrostomy, and Heart Transplant.

He is actively involved in clinical research, co-authoring 618 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Rome, Italy
Other Locations
Milan, Italy
Pisa, 56128, Italy
Genoa, Italy
Gesu, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
Enrollment Status: Terminated
Publish Date: March 31, 2026
Intervention Type: Other, Drug
Study Drug: Vatiquinone
Study Phase: Phase 2/Phase 3
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: January 26, 2026
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 2
Clinical and Genetic Analysis of Autosomal Recessive Forms of Cerebellar Ataxias and Spastic Paraplegias
Clinical and Genetic Analysis of Autosomal Recessive Forms of Cerebellar Ataxias and Spastic Paraplegias
Enrollment Status: Completed
Publish Date: February 04, 2025
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Enrollment Status: Completed
Publish Date: May 08, 2024
Intervention Type: Drug
Study Drug: REN001
Study Phase: Phase 2
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)
Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)
Enrollment Status: Completed
Publish Date: June 07, 2018
View 6 Less Clinical Trials

616 Total Publications

Publisher Correction: Biallelic variants in RNU2-2 cause the most prevalent known recessive neurodevelopmental disorder.
Publisher Correction: Biallelic variants in RNU2-2 cause the most prevalent known recessive neurodevelopmental disorder.
Journal: Nature genetics
Published: April 23, 2026

Frequently Asked Questions about Enrico S. Bertini

Is Enrico S. Bertini a top-rated expert for Spinal Muscular Atrophy (SMA)?

MediFind is an objective health platform that identifies experts based on real-world data. Enrico S. Bertini is classified as an Elite expert for Spinal Muscular Atrophy (SMA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Enrico S. Bertini participate in research or clinical trials?

Yes. Enrico S. Bertini has published 616 articles and abstracts on conditions like Spinal Muscular Atrophy (SMA). You can view a list of Enrico S. Bertini's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bertini's expertise for a condition
ConditionClose
View All 35 Distinguished Conditions
View All 44 Advanced Conditions
View All 146 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile